Impact of Pharmaceutical Interventions with STOPP/START and PIM-Check in Older Hospitalized Patients: A Randomized Controlled Trial

Akram Farhat, Amal Al-Hajje, Pierre-Olivier Lang, Chantal Csajka, Akram Farhat, Amal Al-Hajje, Pierre-Olivier Lang, Chantal Csajka

Abstract

Introduction: Pharmaceutical interventions can reduce negative outcomes related to potentially inappropriate prescriptions (PIPs).

Objective: The objective of this study was to compare the impact of interventions on the reduction of PIPs and on different clinical outcomes using two electronic explicit tools.

Methods: A randomized controlled trial was conducted in patients hospitalized between 2018 and 2019 at the Acute Care for Elders unit at Lausanne University Hospital in Switzerland. A medication review was conducted using PIM-Check in the first arm and STOPP/START in the second arm. Proposed interventions were communicated to the physicians. Clinical outcomes evaluated were incidence of falls, delirium, activities of daily living (ADL), length of stay, number of drugs at discharge and hospital readmission.

Results: The 123 included patients (60 in the first arm and 63 in the second arm) were 86.3 ± 6.6 years old, had 3.5 ± 1.7 diseases and were treated by 6.2 ± 2.7 drugs at admission. There was a significant decrease in PIPs in each arm, but no significant difference between arms. The deprescription of nervous system drugs was significantly higher with STOPP/START than with PIM-Check (Chi-square p = 0.025). ADL scores between home and discharge were significantly higher in the STOPP/START arm than in the PIM-Check arm (4.42 vs 3.77; p = 0.040). The predictors of ADL score improvement were the deprescription of nervous system drugs (β = 0.423; 95% CI 0.034-0.812; p = 0.033), the use of STOPP/START (β = 0.798, 95% CI 0.305-1.290; p = 0.002) and a shorter length of hospital stay (β = -0.033, 95% CI - 0.056 to - 0.010; p = 0.005).

Conclusions: Although PIM-Check was non-inferior to STOPP/START in reducing the number of PIPs, STOPP/START had a significantly higher impact on ADL. The use of STOPP/START or the deprescription of two nervous system drugs would allow the patient to acquire almost one more basic function of living. On the other hand, a loss of one point on the ADL score was observed per month of hospitalization.

Clinical trials registration number: NCT04028583.

Conflict of interest statement

All authors declare that they have no conflict of interest.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
ADL variation between groups. *Significant difference between STOPP/START and PIM-Check

References

    1. Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013;35:75–83. doi: 10.1093/epirev/mxs009.
    1. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. doi: 10.1186/s12877-017-0621-2.
    1. Assiri GA, Shebl NA, Mahmoud MA, et al. What is the epidemiology of medication errors, error-related adverse events and risk factors for errors in adults managed in community care contexts? A systematic review of the international literature. BMJ Open. 2018;8(5):e019101. doi: 10.1136/bmjopen-2017-019101.
    1. Farhat A, Abou-Karroum R, Panchaud A, Csajka C, Al-Hajje A. Impact of pharmaceutical interventions in hospitalized patients: a comparative study between clinical pharmacist and explicit criteria-based tool. Curr Therap Res. 2021 doi: 10.1016/j.curtheres.2021.100650.
    1. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166(9):955–964. doi: 10.1001/archinte.166.9.955.
    1. Blassmann U, Morath B, Fischer A, Knoth H, Hoppe-Tichy T. Medication safety in hospitals: integration of clinical pharmacists to reduce drug-related problems in the inpatient setting. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018;61(9):1103–1110. doi: 10.1007/s00103-018-2788-x.
    1. De Rijdt T, Willems L, Simoens S. Economic effects of clinical pharmacy interventions: a literature review. Am J Health-Syst Pharm AJHP. 2008;65(12):1161–1172. doi: 10.2146/ajhp070506.
    1. Farhat A, Al-Hajje A, Csajka C, Panchaud A. Clinical and economic impacts of explicit tools detecting prescribing errors: a systematic review. J Clin Pharm Ther. 2021;46(4):877–886. doi: 10.1111/jcpt.13408.
    1. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–218. doi: 10.1093/ageing/afu145.
    1. Lang PO, Farhat A, Csajka C. [Optimizing one’s prescriptions: Which approach, which tool to use?] Optimiser ses prescriptions : quelle démarche et quel outil ? La Rev Gériatr. 2017;42(4):207–218.
    1. Desnoyer A, Blanc AL, Pourcher V, et al. PIM-Check: development of an international prescription-screening checklist designed by a Delphi method for internal medicine patients. BMJ Open. 2017;7(7):e016070. doi: 10.1136/bmjopen-2017-016070.
    1. Farhat A, Al-Hajje A, Rachidi S, Zein S, Zeid MB, Salameh P, Bawab W, Awada S. Risk factors and quality of life of dyslipidemic patients in Lebanon: a cross-sectional study. J Epidemiol Glob Health. 2016;6(4):315–323. doi: 10.1016/j.jegh.2016.10.001.
    1. O'Connor MN, O'Sullivan D, Gallagher PF, Eustace J, Byrne S, O'Mahony D. Prevention of hospital-acquired adverse drug reactions in older people using screening tool of older persons' prescriptions and screening tool to alert to right treatment criteria: a cluster randomized controlled trial. J Am Geriatr Soc. 2016;64(8):1558–1566. doi: 10.1111/jgs.14312.
    1. Frankenthal D, Lerman Y, Kalendaryev E, Lerman Y. Intervention with the screening tool of older persons potentially inappropriate prescriptions/screening tool to alert doctors to right treatment criteria in elderly residents of a chronic geriatric facility: a randomized clinical trial. J Am Geriatr Soc. 2014;62(9):1658–1665. doi: 10.1111/jgs.12993.
    1. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg (London, England). 2012;10(1):28–55. doi: 10.1016/j.ijsu.2011.10.001.
    1. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308(24):2594–2604. doi: 10.1001/jama.2012.87802.
    1. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health, ATC/DDD index 2019. . Accessed 10 Nov 2019.
    1. World Health Organization (2018), Falls. . Accessed 10 Nov 2019.
    1. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990;113(12):941–948. doi: 10.7326/0003-4819-113-12-941.
    1. Farhat A, Panchaud A, Al-Hajje A, Lang PO, Csajka C. Ability to detect Potentially Inappropriate Prescriptions in older patients: comparative analysis between PIM-Check and STOPP/STARTv2. Eur J Clin Pharmacol. 2021;77(11):1747–1756. doi: 10.1007/s00228-021-03171-4.
    1. Urfer M, Elzi L, Dell-Kuster S, Bassetti S. Intervention to improve appropriate prescribing and reduce polypharmacy in elderly patients admitted to an internal medicine unit. PLoS ONE. 2016;11(11):e0166359. doi: 10.1371/journal.pone.0166359.
    1. Dalleur O, Boland B, Losseau C, et al. Reduction of potentially inappropriate medications using the STOPP criteria in frail older inpatients: a randomised controlled study. Drugs Aging. 2014;31(4):291–298. doi: 10.1007/s40266-014-0157-5.
    1. Michalek C, Wehling M, Schlitzer J, Frohnhofen H. Effects of "Fit fOR The Aged" (FORTA) on pharmacotherapy and clinical endpoints–a pilot randomized controlled study. Eur J Clin Pharmacol. 2014;70(10):1261–1267. doi: 10.1007/s00228-014-1731-9.
    1. Gallagher PF, O'Connor MN, O'Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011;89(6):845–854. doi: 10.1038/clpt.2011.44.
    1. Wehling M, Burkhardt H, Kuhn-Thiel A, et al. VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing. 2016;45(2):262–267. doi: 10.1093/ageing/afv200.
    1. Zhanga Y, Jiaa H, Lib A, Liuc J, Li H. Study on prediction of activities of daily living of the aged people based on longitudinal data. Proc Comput Sci. 2016;91:470–477. doi: 10.1016/j.procs.2016.07.122.
    1. Pharmacy Practice Research Abstracts. Can Pharm J (Ott). 2019 Sep 6;152(5):S1–S43. doi: 10.1177/1715163519874072. (PMCID: PMC6739658).

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi